COMT and Parkinson disease: Like tafamidis, the catechol-O-methyltransferase (COMT) inhibitor tolcapone, approved for the treatment of Parkinson’s disease, has a TTR stabilizing effect [40] with a greater capacity to cross the blood–brain barrier [41, 42].